Through professional development activities, FDA meets the regulatory challenges posed by new science and technology developments. In addition to supporting a broad regulatory science program—including professional development components—FDA fosters collaborative activities with scientific institutions, academia, and industry.
Achieving Data Quality & Integrity in Maximum Containment Laboratories
POSTPONED April 20-24, 2020 (Bethesda, Maryland) - Annual course to help address challenges associated with ensuring data quality and integrity in regulated studies conducted in BSL-4 laboratories to support MCM development.
Data Quality & Integrity in Clinical Trials Involving High-Consequence Pathogens
New date: October 26-28, 2020 (virtual only) - Annual course focused on the preparation and execution of research clinical trials to facilitate approval of MCMs for high-consequence pathogens.
About MCMi Professional Development
Learn about training to help FDA and MCM developers meet regulatory challenges posed by new science and technology.
MCMi news and events
News and events from the FDA Office of Counterterrorism and Emerging Threats (OCET), Medical Countermeasures Initiative (MCMi), and federal and industry partners.